Amoxicillin

ATC J01CA04 · WHO DDD 1.5 g (oral) · 500 mg capsule

Class: Antibacterials for systemic use. ATC code J01CA04 stands for "amoxicillin" in the WHO index, whose DDD is 1.5 g by the oral route [1].

WHO Model List of Essential Medicines 2025: listed, core list, also on the children’s list [2].

Indications on the WHO list (12)
  • Acute pharyngitis · core list · children’s list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2017
  • Periapical abscess without sinus · core list · children’s list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2019
  • Acute sinusitis · core list · children’s list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2017
  • Acute otitis media · core list · children’s list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2017
  • Chronic obstructive pulmonary disease with acute exacerbation · core list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2017
  • Acute malnutrition in infants, children or adolescents · core list · children’s list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2017
  • Acute malnutrition in infants, children or adolescents · core list · children’s list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2017
  • Bacterial pneumonia · core list · children’s list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2017
  • Bacterial pneumonia · core list · children’s list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2017
  • Sepsis without septic shock · core list · children’s list · First choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2023
  • Bacterial meningitis · core list · children’s list · Second choice · 6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics · first added 2017
  • Bacterial meningitis · core list · children’s list · Second choice · 5. Medicines for neurological disorders 5.1. Medicines for central nervous system disorders 5.1.6. Medicines for central nervous system infections 5.1.6.1. Medicines for bacterial central nervous system infections · first added 2025

The WHO electronic list states that the 2025 PDF lists are binding: adults’ list, children’s list.

Summary by country, in euros at the ECB rate of 9 October 2026 [3]
CountryPacksKind of figure Cost per DDDAnnual cost at the WHO standard dose
France 14 List price €0.64 €232.69
Spain 14 List price €0.40 to €0.53 €146.00 to €191.62
United Kingdom 2 Reimbursement tariff €0.20 €73.20 £62.05

Names, authorisations and literature

Trade names (37)
France (24)
AMOXICILLINE ALMUS, AMOXICILLINE ALMUS PHARMA, AMOXICILLINE ARROW, AMOXICILLINE ARROW LAB, AMOXICILLINE BENTA, AMOXICILLINE BGR, AMOXICILLINE BIOGARAN, AMOXICILLINE CRISTERS, AMOXICILLINE EG, AMOXICILLINE EG LABO, AMOXICILLINE EVOLUGEN, AMOXICILLINE KRKA, AMOXICILLINE PANPHARMA, AMOXICILLINE SANDOZ, AMOXICILLINE TEVA, AMOXICILLINE TEVA SANTE, AMOXICILLINE VIATRIS, AMOXICILLINE VIATRIS PHARMA, AMOXICILLINE VIATRIS SANTE, AMOXICILLINE ZENTIVA LAB, AMOXICILLINE ZYDUS, AMOXICILLINE ZYDUS FRANCE, CLAMOXYL, XYLLOMAC [4]
Spain (13)
AMOXICILINA ALMUS, AMOXICILINA ALTER, AMOXICILINA ARDINE, AMOXICILINA AUROVITAS, AMOXICILINA CINFA, AMOXICILINA COMBIX, AMOXICILINA NORMON, AMOXICILINA PENSA PHARMA, AMOXICILINA RATIOPHARM, AMOXICILINA SANDOZ, AMOXICILINA SANDOZ FARMACEUTICA, AMOXICILINA TEVA, CLAMOXYL [5]

Links lead to the official product page: the EPAR for the European Union, the public medicines database for France, the CIMA summary of product characteristics for Spain, the dm+d for the United Kingdom. An asterisk marks a name taken from the DysNet register only.

European public assessment reports, EPAR (0)

The European Medicines Agency's list holds no medicine with ATC code J01CA04: this medicine has no EPAR [6].

Literature (PubMed, 28,738 papers)

PubMed counts 28,738 papers on this medicine [7]. The selection gives the most recent of each type; the Method page says how it is made. See the search in PubMed ↗

Cochrane reviews (56)

  • Esposito MA, et al. Interventions for replacing missing teeth: antibiotic prophylaxis for dental implant placement without bone augmentation procedures. Cochrane Database Syst Rev. 2026. PubMed 42677885 ↗ doi ↗
  • Liu C, et al. Antibiotic treatment for low back pain, radicular pain, or both. Cochrane Database Syst Rev. 2026. PubMed 41944232 ↗ doi ↗
  • Chong LY, et al. Systemic antibiotics for chronic suppurative otitis media. Cochrane Database Syst Rev. 2025. PubMed 40484405 ↗ doi ↗
  • Head K, et al. Topical antiseptics for chronic suppurative otitis media. Cochrane Database Syst Rev. 2025. PubMed 40484403 ↗ doi ↗
  • Chong LY, et al. Topical versus systemic antibiotics for chronic suppurative otitis media. Cochrane Database Syst Rev. 2025. PubMed 40484402 ↗ doi ↗

All 56 results in PubMed ↗

Systematic reviews and meta-analyses (580)
  • Almadhoon H, et al. Global prevalence and guideline adherence of antibiotic prescribing in dental implant surgery: A systematic review and meta-analysis. Jpn Dent Sci Rev. 2026. PubMed 42519815 ↗ doi ↗
  • Hwang JH, et al. Efficacy and safety of tegoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol. 2026. PubMed 42832287 ↗ doi ↗
  • Rao A, et al. Comment on Letter to the Editor "Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis". J Gastroenterol Hepatol. 2026. PubMed 42711277 ↗ doi ↗
  • Jeswani W, et al. Comment on: "Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials". J Gastroenterol Hepatol. 2026. PubMed 42697849 ↗ doi ↗
  • Kumari A, et al. Response to "Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials". J Gastroenterol Hepatol. 2026. PubMed 42684140 ↗ doi ↗

All 580 results in PubMed ↗

Practice guidelines (85)
  • Gisbert JP, et al. VI Spanish Consensus Conference on the treatment of Helicobacter pylori infection. Gastroenterol Hepatol. 2026. PubMed 42816313 ↗ doi ↗
  • Olzowy B. [German S2k guideline on antibiotic therapy of ENT infections : The most important information in brief]. HNO. 2026. PubMed 42230387 ↗ doi ↗
  • Isomoto H, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition. J Gastroenterol. 2026. PubMed 41902905 ↗ doi ↗

All 85 results in PubMed ↗

Health technology assessments (6)

The opinions of the assessment bodies of the pilot countries and of Germany, with a link to each opinion. The status shown is the one each body publishes.

France, HAS Transparency Committee (6)

SMR: actual clinical benefit. ASMR: improvement in actual clinical benefit, from I (major) to V (none). Opinions taken from the BDPM [4].

  • CT-19423 · 8 September 2021 · Inscription (CT) · SMR Important · ASMR V · XYLLOMAC
    Wording of the opinion, in French

    SMR : Le service médical rendu par les spécialités CLAMOXYL (amoxicilline) 500 mg et 1 g, poudre pour solution injectable/ pour perfusion (IM, IV) est important dans les indications de l’AMM.

    ASMR : Ces spécialités sont des compléments de gamme qui n’apportent pas d’amélioration du service médical rendu (ASMR V) par rapport aux autres présentations déjà inscrites.

  • CT-17504 · 9 January 2019 · Inscription (CT) · SMR Important · ASMR V · AMOXICILLINE ARROW LAB
    Wording of the opinion, in French

    SMR : Le service médical rendu par AMOXICILLINE ARROW LAB 1 g, comprimé dispersible est important dans les indications de l’AMM.

    ASMR : Cette spécialité est un générique qui n’apporte pas d’amélioration du service médical rendu (ASMR V) par rapport au princeps CLAMOXYL 1 g, comprimé dispersible.

  • CT-14821 · 6 April 2016 · Inscription (CT) · SMR Important · ASMR V · XYLLOMAC
    Wording of the opinion, in French

    SMR : Le service médical rendu par CLAMOXYL 1 g poudre pour solution injectable (IM, IV) est important dans les indications de l’AMM.

    ASMR : Cette spécialité est un complément de gamme qui n’apporte pas d’amélioration du service médical rendu (ASMR V) par rapport aux autres présentations déjà inscrites.

  • CT-14820 · 6 April 2016 · Renouvellement d'inscription (CT) · SMR Important, Insuffisant · CLAMOXYL
    Wording of the opinion, in French

    SMR : Le service médical rendu par CLAMOXYL reste important dans toutes les indications, excepté dans les surinfections de bronchites aiguës.

    SMR : Le service médical rendu par CLAMOXYL reste insuffisant dans les surinfections de bronchites aiguës.

  • CT-14631 · 23 September 2015 · Inscription (CT) · SMR Important, Insuffisant · ASMR V · AMOXICILLINE ARROW LAB
    Wording of the opinion, in French

    SMR : Le service médical rendu par AMOXICILLINE ARROW LAB 500 mg, gélule, est important dans toutes les autres indications de l’AMM.

    SMR : Le service médical rendu par AMOXICILLINE ARROW LAB 500 mg, gélule, est insuffisant dans le traitement des surinfections des bronchites aiguës.

    ASMR : Cette spécialité est un générique qui n’apporte pas d’amélioration du service médical rendu (ASMR V) par rapport au princeps CLAMOXYL 500 mg, gélule.

  • CT-11890 · 29 February 2012 · Inscription (CT) · SMR Important, Insuffisant · ASMR V · AMOXICILLINE ARROW
    Wording of the opinion, in French

    SMR : Le service médical rendu par ces spécialités est important dans les indications de l'AMM, excepté dans l'indication « surinfections de bronchites aiguës » pour laquelle le service médical rendu est insuffisant.

    SMR : Le service médical rendu par ces spécialités est insuffisant dans l'indication « surinfections de bronchites aiguës ».

    ASMR : Ces spécialités sont des compléments de gamme qui n'apportent pas d'amélioration du service médical rendu (ASMR V).

England, NICE (0)

NICE has published no technology appraisal that names this medicine among the technologies appraised [8].

Scotland, SMC (0)

The Scottish Medicines Consortium has published no advice on this medicine [9].

Germany, G-BA (0)

The G-BA has run no early benefit assessment (AMNOG) of this medicine on its own [10].

Spain, AEMPS therapeutic positioning reports (0)

The AEMPS database of therapeutic positioning reports holds no report on this medicine [11].

How the figure is computed

Example, France: the pack AMOXICILLINE EVOLUGEN 500 mg, gélule, plaquette(s) PVC aluminium de 12 gélule(s), costs €2.55. It holds 6 g, which is 4 DDD. The cost per DDD is €2.55 ÷ 4 = €0.64, and the annual cost at the WHO standard dose, list price, is that cost × 365 = €232.69.

France

Public price in France, including VAT and the per-pack dispensing fee. Source [4], read on 9 October 2026. ATC match: through the active substance (BDPM substance code), since the BDPM gives no ATC code.

Show the 14 packs
ProductPackPrice DDD per packCost per DDDAnnual cost at the WHO standard doseSource line
AMOXICILLINE EVOLUGEN 500 mg, géluleEVOLUPHARM plaquette(s) PVC aluminium de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 60055866 / CIP13 3400930311387substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE VIATRIS 500 mg, géluleVIATRIS SANTE plaquette(s) thermoformée(s) PVC-aluminium PVDC de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 60424338 / CIP13 3400934913174substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE ZENTIVA LAB 500 mg, géluleGLAXOSMITHKLINE plaquette(s) aluminium PVC PVDC de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 61096912 / CIP13 3400927929335substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE CRISTERS 500 mg, géluleCRISTERS plaquette(s) PVC aluminium de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 64011803 / CIP13 3400930069097substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE CRISTERS 500 mg, géluleCRISTERS plaquette(s) PVC TE (thermo-élastique) PVDC aluminium de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 64011803 / CIP13 3400930246993substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE EG LABO 500 mg, géluleEG LABO - LABORATOIRES EUROGENERICS plaquette(s) PVC TE (thermo-élastique) PVDC aluminium de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 64529639 / CIP13 3400930219911substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE ZYDUS FRANCE 500 mg, géluleZYDUS FRANCE plaquettes thermoformées (PVC/aluminium) et Aluminium PVC/TE/PVDC de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 64727464 / CIP13 3400927590313substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE TEVA SANTE 500 mg, géluleTEVA (PAYS-BAS) plaquette(s) PVC TE (thermo-élastique) PVDC aluminium de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 65171903 / CIP13 3400930242360substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE ARROW LAB 500 mg, géluleARROW GENERIQUES plaquette(s) PVC (ACLAR RX) polytrifluorochloroéthylène aluminium de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 66916798 / CIP13 3400927937729substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE SANDOZ 500 mg, géluleSANDOZ plaquette(s) PVC PVDC aluminium de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 67410088 / CIP13 3400936796010substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE BENTA 500 mg, géluleBENTA (FRANCE) plaquette(s) PVC-Aluminium de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 67459306 / CIP13 3400930178614substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
CLAMOXYL 500 mg, géluleGLAXOSMITHKLINE plaquette(s) PVC PVC-Aluminium PVDC de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 67707794 / CIP13 3400931587538substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE ALMUS PHARMA 500 mg, géluleALMUS FRANCE plaquette(s) aluminium PVC de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 68695334 / CIP13 3400930162408substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm
AMOXICILLINE BIOGARAN 500 mg, géluleGLAXOSMITHKLINE plaquette(s) aluminium PVC de 12 gélule(s) €2.55 4 €0.64 €232.69 CIS 69118175 / CIP13 3400933857042substance code 28165 (AMOXICILLINE TRIHYDRATÉE) in CIS_COMPO_bdpm

Spain

Retail price including VAT (PVP IVA). Source [12][5], read on 9 October 2026. ATC match: ATC code of each national code, checked in CIMA.

Show the 14 packs
ProductPackPrice DDD per packCost per DDDAnnual cost at the WHO standard doseSource line
AMOXICILINA NORMON 500 MG CAPSULAS DURAS EFG , 30 capsulasNORMON S.A. 30 capsulas €4.00 10 €0.40 €146.00 Código Nacional 694731AEMPS CIMA, registration 62437
AMOXICILINA ARDINE 500 mg CAPSULAS EFG, 30 capsulasREIG JOFRE S.A. 30 capsulas €4.00 10 €0.40 €146.00 Código Nacional 694740AEMPS CIMA, registration 51714
AMOXICILINA SANDOZ 500 mg CAPSULAS EFG, 30 capsulasSANDOZ FARMACEUTICA, S.A 30 capsulas €4.00 10 €0.40 €146.00 Código Nacional 695001AEMPS CIMA, registration 62338
CLAMOXYL 500 mg CAPSULAS, 30 capsulasGLAXOSMITHKLINE, S.A. 30 capsulas €4.00 10 €0.40 €146.00 Código Nacional 695335AEMPS CIMA, registration 50239
AMOXICILINA ALMUS 500 MG CAPSULAS DURAS EFG, 30 capsulas (Blister Al/PVC)ALMUS FARMACEUTICA, S.A.U. 30 capsulas €4.00 10 €0.40 €146.00 Código Nacional 721825AEMPS CIMA, registration 83136
AMOXICILINA ALTER 500 MG CAPSULAS DURAS EFG, 30 capsulasALTER S.A. 30 capsulas €4.00 10 €0.40 €146.00 Código Nacional 724779AEMPS CIMA, registration 83825
AMOXICILINA PENSA PHARMA 500 MG CAPSULAS DURAS EFG, 30 capsulasTOWA PHARMACEUTICAL, S.A. 30 capsulas €4.00 10 €0.40 €146.00 Código Nacional 725906AEMPS CIMA, registration 84173
AMOXICILINA NORMON 500 MG CAPSULAS DURAS EFG , 20 capsulasNORMON S.A. 20 capsulas €3.50 6.67 €0.53 €191.62 Código Nacional 694730AEMPS CIMA, registration 62437
AMOXICILINA ARDINE 500 mg CAPSULAS EFG, 20 capsulasREIG JOFRE S.A. 20 capsulas €3.50 6.67 €0.53 €191.62 Código Nacional 694739AEMPS CIMA, registration 51714
AMOXICILINA SANDOZ 500 mg CAPSULAS EFG, 20 capsulasSANDOZ FARMACEUTICA, S.A 20 capsulas €3.50 6.67 €0.53 €191.62 Código Nacional 695000AEMPS CIMA, registration 62338
CLAMOXYL 500 mg CAPSULAS, 20 capsulasGLAXOSMITHKLINE, S.A. 20 capsulas €3.50 6.67 €0.53 €191.62 Código Nacional 695334AEMPS CIMA, registration 50239
AMOXICILINA ALMUS 500 MG CAPSULAS DURAS EFG, 20 capsulas (Blister Al/PVC)ALMUS FARMACEUTICA, S.A.U. 20 capsulas €3.50 6.67 €0.53 €191.62 Código Nacional 721824AEMPS CIMA, registration 83136
AMOXICILINA ALTER 500 MG CAPSULAS DURAS EFG, 20 capsulasALTER S.A. 20 capsulas €3.50 6.67 €0.53 €191.62 Código Nacional 724778AEMPS CIMA, registration 83825
AMOXICILINA PENSA PHARMA 500 MG CAPSULAS DURAS EFG, 20 capsulasTOWA PHARMACEUTICAL, S.A. 20 capsulas €3.50 6.67 €0.53 €191.62 Código Nacional 725905AEMPS CIMA, registration 84173

United Kingdom

Drug Tariff basic price paid to the pharmacy, excluding VAT (Part VIIIA Category M). Source [13][14], read on 9 October 2026. ATC match: ATC code of the virtual product (VMP) in the dm+d.

Show the 2 packs
ProductPackPrice DDD per packCost per DDDAnnual cost at the WHO standard doseSource line
Amoxicillin 500mg capsules 15 capsule £0.85 5 £0.17 £62.05€73.20 VMPP SNOMED 10741811000001101dm+d browser, VMP 240
Amoxicillin 500mg capsules 21 capsule £1.19 7 £0.17 £62.05€73.20 VMPP SNOMED 1037711000001109dm+d browser, VMP 240

References

  1. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2026 [Internet]. Oslo: Norwegian Institute of Public Health; [updated 2026 Jan 20; cited 2026 Oct 9]. Available from: https://atcddd.fhi.no/atc_ddd_index/
  2. World Health Organization. Electronic Essential Medicines List (eEML) [Internet]. Geneva: WHO; [cited 2026 Oct 9]. Available from: https://list.essentialmeds.org/
  3. European Central Bank. Euro foreign exchange reference rates, 9 October 2026 [Internet]. Frankfurt am Main: ECB; 2026 [cited 2026 Oct 9]. Available from: https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/index.en.html
  4. Base de données publique des médicaments [Internet]. Paris: Ministère du Travail, de la Santé, des Solidarités et des Familles; 2026 [updated 2026 Oct 8; cited 2026 Oct 9]. Available from: https://base-donnees-publique.medicaments.gouv.fr/telechargement
  5. Agencia Española de Medicamentos y Productos Sanitarios. CIMA: Centro de información de medicamentos [Internet]. Madrid: AEMPS; [cited 2026 Oct 9]. Available from: https://cima.aemps.es/cima/
  6. European Medicines Agency. Download medicine data [Internet]. Amsterdam: EMA; 2026 [updated 2026 Oct 9; cited 2026 Oct 9]. Available from: https://www.ema.europa.eu/en/medicines/download-medicine-data
  7. PubMed [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2026 Oct 9]. Available from: https://pubmed.ncbi.nlm.nih.gov/
  8. National Institute for Health and Care Excellence. Technology appraisal guidance [Internet]. London: NICE; [cited 2026 Oct 9]. Available from: https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance
  9. Scottish Medicines Consortium. Medicines advice [Internet]. Glasgow: SMC; [cited 2026 Oct 9]. Available from: https://scottishmedicines.org.uk/medicines-advice/
  10. Gemeinsamer Bundesausschuss. Nutzenbewertung nach § 35a SGB V: Apixaban [Internet]. Berlin: G-BA; [cited 2026 Oct 9]. Available from: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/
  11. Agencia Española de Medicamentos y Productos Sanitarios. Informes de posicionamiento terapéutico [Internet]. Madrid: AEMPS; [cited 2026 Oct 9]. Available from: https://www.aemps.gob.es/medicamentos-de-uso-humano/evaluacion-de-tecnologias-sanitarias/informes-de-posicionamiento-terapeutico/
  12. Ministerio de Sanidad. Nomenclátor de facturación de octubre 2026 [Internet]. Madrid: Ministerio de Sanidad; 2026 [cited 2026 Oct 9]. Available from: https://www.sanidad.gob.es/profesionales/nomenclator.do
  13. NHS Business Services Authority. Drug Tariff Part VIIIA, October 2026 [Internet]. Newcastle upon Tyne: NHSBSA; 2026 [cited 2026 Oct 9]. Available from: https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff/drug-tariff-part-viii
  14. NHS Business Services Authority. dm+d browser: NHS dictionary of medicines and devices [Internet]. Newcastle upon Tyne: NHSBSA; [updated 2026 Oct 1; cited 2026 Oct 9]. Available from: https://dmd-browser.nhsbsa.nhs.uk/